TeraImmune main image
teraimmune logo
  • A company developing customized cell therapies for autoimmune diseases using the patient’s own Treg cells
  • C-Corporation in the United States
  • Three patented technologies related to Treg cell production and receptors
  • Three Pipelines
    • Hemophilia A
    • Multiple Sclerosis
    • B cell lymphoma
  • Public Achievements
    • SBIR Phase | (NHLBI, NIH)
    • Production Assistance for Cellular Therapies(PACT) award(NHLBI, NIH)
    • www.pactgroup.net

2016

  • Establish TeraImmune, LLC

2017

  • 3rd place Prize winner of the SAPA-GP Startup Pitch Contest

2018

  • Awarded SBIR (Small Business Innovation Research) Phase I, NHLBI, NIH
  • Awarded the Montgomery County SBIR Matching Fund
  • Received the PACT Service Task from NHLBI, NIH (www.pactgroup.net)

2019

  • Convert to TeraImmune, Inc
  • INTERACT (pre-pre-IND) meeting with CBER, FDA
  • Designated Moffitt Cancer Center as a cGMP facility for the Treg Manufacturing (pre-IND)
  • Secured Exclusive Licenses from HJF
  • Completed the Seed Round Investment

Vision

To Create a World without Autoimmune Diseases

Mission

To Help Patients Return to Daily Life

Goal

To Develop Innovative Cell Therapy with the Patient’s Own Immune Cells

Background image
세포치료제 설명

TeraImmune's Disease Specific Treg Cell Therapy

Regulatory T cells (Tregs) are essential immune cells that balance the body’s immune system.
세포치료제 설명
Customized Treg Production Process
Treg Experts/Know-how
Treg Cell Culture Technology
Disease Specific Receptors

Disease Specific Treg Cell Therapy

세포치료제 설명

Disease Specific Treg Cell Therapy

세포치료제
background 2

Pipeline

파이프라인 파이프라인
Staffs

Operations and Management

Yong Chan Kim, CEO
Yong Chan Kim
Chief Executive Officer
  • Founder of TeraImmune, Inc
  • Ph.D. in Biochemistry, Chungnam National University
  • Former NIH Researcher and DoD USU Research Professor
Jihoon Park, COO
Jihoon Park
Chief Operation Officer
  • Co-Founder of TeraImmune, Inc
  • Ph.D. in Biochemistry, Chungnam National University
  • Former NIH Researcher

Management Advisory

Nick Hammond, PhD, Medicinal Chem at U Mississippi
Nick Hammond
  • PhD, Medicinal Chem at U Mississippi
  • Co-founder at Albitech, Inc. (2006-2011)
  • Executive director at UMD system

Technical Advisory

Ethan M. Shevach, MD
Ethan M. Shevach, MD
  • Senior principle investigator, NIAID, NIH

Research and Project Management

Si Hyug Jang
Si Hyug Jang
Project Manager
  • Ph.D. in Immunology, Temple University
  • Former U Michigan and DoD USU Researcher
Heekyong (Rachel) Bae
Heekyong (Rachel) Bae
Project Manager
  • Ph.D. in Immunotoxicology, Michigan State University
  • Former U Michigan and NCI Researcher
Jae Woo Hong
Jae Woo Hong
Project Manager
  • D.V.M. and Ph.D. Konkuk University
  • Former Harvard Medical and NCI Researcher